 Merck Co. Inc. MRK, 0.17 and Moderna Inc. MRNA, -6.89 said Tuesday that their experimental mRNA-based cancer vaccine reduced the risk of recurrence or death when used with Mercks Keytruda in patients with late-stage melanoma. Mercks stock was up 1.9 in premarket trading, while Moderna shares rallied 5.6. 